Overview

A Study for the Treatment of Metastatic Prostate Cancer With HRS-1167 Tablets Combined With Abiraterone Acetate Tablets and Prednisone

Status:
RECRUITING

Trial end date:
2026-12-31

Target enrollment:

Participant gender:

Summary

The purpose of this study was to observe and evaluate the tolerability, safety, and pharmacokinetics of HRS-1167 combined with abiraterone acetate tablets (II) and prednisone in patients with metastatic prostate cancer, determine the RP2D, and evaluate the effectiveness.

Phase:

PHASE1

Details

Lead Sponsor:

Jiangsu HengRui Medicine Co., Ltd.

Treatments:

Prednisone